Last Updated: June 22, 2026

Patent: 8,663,945

✉ Email this page to a colleague

Summary for Patent: 8,663,945

Title:	Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
Abstract:	The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
Inventor(s):	Pla; Itzcoatl A. (Worcester, MA), Matuck; Joseph C. (Worcester, MA), Fann; John C. (Shrewsbury, MA), Schulz; Christof (Ayer, MA), Roy; Nicole A. (Worcester, MA), Bruton; David F. (Enfield, CT), McIntire; James (Castro Valley, CA), Yu-Hsiang; David Chang (Solana Beach, CA), Seewoester; Thomas (Simi Valley, CA)
Assignee:	AbbVie Inc (North Chicago, IL)
Application Number:	13/308,075
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,663,945
Patent Claims:	see list of patent claims

Details for Patent 8,663,945

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	8,663,945	2031-11-30
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	8,663,945	2031-11-30
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	8,663,945	2031-11-30
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	September 23, 2014	8,663,945	2031-11-30
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	November 23, 2015	8,663,945	2031-11-30
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	March 09, 2016	8,663,945	2031-11-30
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	October 17, 2016	8,663,945	2031-11-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,663,945

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2007294731	⤷ Start Trial
Brazil	PI0716762	⤷ Start Trial
Canada	2663442	⤷ Start Trial
Canada	2842959	⤷ Start Trial
Canada	2842964	⤷ Start Trial
Canada	2842966	⤷ Start Trial
Canada	2910619	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.